Table 1.
Patient's main characteristics at baseline and along the treatment.
| Case presentation | |
|---|---|
| Classification | B-precursor ALL Ph+ |
| WBC (μl)/Hb (g/dl)/platelets (μl) | 40,000/8.7/87,000 |
| Blasts | 80% |
| Blasts phenotypes | CD19+, CD20–, CD10bright, CD45dim, CD34+, CD58+, CD5–, CD38low |
| BCR-ABL isoform | P210 |
| Induction regimen | Vincristine + Dasatinib |
| CD34+ cell dose during transplant | 4.6 × 106/kg |
| GVHD prophylaxis | Cyclosporin, MTX |
| Time from transplantation to relapse (months) | 16 |
| Treatment after relapse | DLI + ponatinib |
| Current status | Alive in molecular remission |
| Time from diagnosis (months) | 45 |